Corporate Board Profile
Tech Score: 17/100
1 mention(s) identify SAFI R. BAHCALL, PH.D. as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | 2013-04-29 | Dr. Bahcall also co-founded a drug discovery company focused on novel ion channel research in November 2001, which was acquired by Synta in December 2002. He received his B.A. summa cum laude from Harvard University, was awarded his Ph.D. from Stanford University in theoretical physics, and was a Miller postdoctoral research fellow at the University of California, Berkeley. | Dr. Bahcall has a Ph.D. in theoretical physics from Stanford University and was a Miller postdoctoral research fellow at UC Berkeley, indicating strong technical and quantitative skills. He co-founded a drug discovery company focused on novel ion channel research, showing involvement in scientific and technical innovation. His background suggests capability in technical and scientific areas that likely include programming or related skills. |
| Filing Date | Source Excerpt |
|---|---|
| 2008-04-29 | Dr. Bahcall received his B.A. summa cum laude from Harvard University, was awarded his Ph.D. from Stanford University in theoretical physics, and was a Miller postdoctoral research fellow at the University of California, Berkeley. |
| 2009-04-30 | Dr. Bahcall received his B.A. summa cum laude from Harvard University, was awarded his Ph.D. from Stanford University in theoretical physics, and was a Miller postdoctoral research fellow at the University of California, Berkeley. |
| 2010-04-30 | Dr. Bahcall received his B.A. summa cum laude from Harvard University, was awarded his Ph.D. from Stanford University in theoretical physics, and was a Miller postdoctoral research fellow at the University of California, Berkeley. Our Board of Directors has concluded that Dr. Bahcall should serve as a director as of the date of this proxy statement because, as our Chief Executive Officer and our co-founder, he has an extensive understanding of our R&D programs, detailed knowledge of our current and prior business activities and strategic insights based on his business experience. |
| 2011-04-29 | He received his B.A. summa cum laude from Harvard University, was awarded his Ph.D. from Stanford University in theoretical physics, and was a Miller postdoctoral research fellow at the University of California, Berkeley. |
| 2012-04-27 | He received his B.A. summa cum laude from Harvard University, was awarded his Ph.D. from Stanford University in theoretical physics, and was a Miller postdoctoral research fellow at the University of California, Berkeley. |
| 2013-04-29 | Dr. Bahcall also co-founded a drug discovery company focused on novel ion channel research in November 2001, which was acquired by Synta in December 2002. He received his B.A. summa cum laude from Harvard University, was awarded his Ph.D. from Stanford University in theoretical physics, and was a Miller postdoctoral research fellow at the University of California, Berkeley. |
Data sourced from SEC filings. Last updated: 2026-02-03